资源描述:
《2011肥厚型心肌病(hcm)诊治指南课件_1》由会员上传分享,免费在线阅读,更多相关内容在教育资源-天天文库。
1、2011ACCF/AHA肥厚型心肌病(HCM)诊治指南美国胸外科协会、美国超声心动力图学会、美国核心脏病学学会、美国心力衰竭学会、心脏节律学会、心血管造影和介入学会、胸腔外科学会合作开发©AmericanCollegeofCardiologyFoundationandAmericanHeartAssociation,Inc.广西柳州市人民医院心内科胡世红教授译引证这套幻灯片改编自2011ACCF/AHA肥厚型心肌病诊治指南(JournaloftheAmericanCollegeofCardiology).2011-11-08发表,在下述网站可找到:http://content.online
2、jacc.org/cgi/content/full/j.jacc.2011.06.011指南全文在下述网站也可找到:ACC(www.cardiosource.org)andAHA(my.americanheart.org)SlideSetEditorsBernardJ.Gersh,MB,ChB,DPhil,FACC,FAHA,Co-ChairBarryJ.Maron,MD,FACC,Co-ChairTheDiagnosisandTreatmentofHCMGuidelineWritingCommitteeMembersBernardJ.Gersh,MB,ChB,DPhil,FACC,FAHA
3、,Co-ChairBarryJ.Maron,MD,FACC,Co-ChairSpecialThanksToSteveR.Ommen,MD,FACC,FAHAHarryRakowski,MD,FACC,FASEChristineE.Seidman,MD,FAHAJeffreyA.Towbin,MD,FACC,FAHAJamesE.Udelson,MD,FACC,FASNCClydeW.Yancey,MD,FACC,FAHARobertO.Bonow,MD,MACC,FAHAJosephA.Dearani,MD,FACCMichaelA.Fifer,MD,FACC,FAHAMarkS.Link,
4、MD,FACC,FHRSSrihariS.Naidu,MD,FACC,FSCAIRickA.Nishimura,MD,FACC,FASE推荐类别和证据水平ArecommendationwithLevelofEvidenceBorCdoesnotimplythattherecommendationisweak.Manyimportantclinicalquestionsaddressedintheguidelinesdonotlendthemselvestoclinicaltrials.Althoughrandomizedtrialsareunavailable,theremaybeavery
5、clearclinicalconsensusthataparticulartestortherapyisusefuloreffective.*Dataavailablefromclinicaltrialsorregistriesabouttheusefulness/efficacyindifferentsubpopulations,suchassex,age,historyofdiabetes,historyofpriormyocardialinfarction,historyofheartfailure,andprioraspirinuse.†Forcomparativeeffective
6、nessrecommendations(ClassIandIIa;LevelofEvidenceAandBonly),studiesthatsupporttheuseofcomparatorverbsshouldinvolvedirectcomparisonsofthetreatmentsorstrategiesbeingevaluated.诊断GuidelineforHCM基因检测策略/家族筛查Diagnosis作为HCM患者评估的一部分推荐进行家族性遗传评估和遗传咨询。进行了基因检测的患者还应当由心血管病遗传知识渊博的专家进行遗传咨询,以便能与患者一起回顾检测结果及其临床意义。对于HCM
7、患者的一级亲属推荐筛查(临床的,伴或不伴基因检测)。对于有不典型HCM临床表现的患者或当怀疑另一种遗传疾病是原因时,推荐基因检测HCM和其它不能解释的心脏肥厚遗传起因。基因检测策略/家族筛查IIIaIIbIIIBIIIaIIbIIIBIIIaIIbIIIBIIIaIIbIIIB对源头患者行基因检测以促进存在发生HCM风险的一级家族成员的检出是合理的。基因检测在HCM心源性猝死风险评估中的用途尚不明确。基因检测